Real-World Evidence in mCRC: Special Populations and Safety Assessment
Panelists discuss how RWE informs treatment and safety decisions for special populations such as patients with ECOG PS 2 with metastatic colorectal cancer.
Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
Panelists discuss how PROs, particularly tolerability and fatigue, guide shared decision-making for third-line therapy in mCRC.
Translating Real-World Outcomes in mCRC Into Patient Conversations
Panelists discuss how real-world outcomes inform patient conversations and support shared decision-making for third-line metastatic colorectal cancer therapies.
Leveraging Real-World Evidence in Sequencing Decisions for mCRC
Panelists discuss how RWE helps guide sequencing choices when head-to-head trial data are lacking in third-line metastatic colorectal cancer.
Selecting Among Third-Line Therapies in Clinical Practice for mCRC
Panelists discuss how efficacy, safety, quality of life, and patient-specific factors drive selection among third-line therapies in metastatic colorectal cancer.
Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
Panelists discuss how data from FRESCO-2 and other trials position fruquintinib as a strong third-line option compared with regorafenib and FTD/TPI.
Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
Panelists discuss how the SUNLIGHT trial and real-world evidence support FTD/TPI with or without bevacizumab as an effective third-line option in metastatic colorectal cancer.
Overview of Available Third-Line Options in mCRC
Panelists discuss how available third-line therapies, such as FTD/TPI, regorafenib, and others, are chosen based on survival data, safety, and patient quality of life.
